The JAK2V617F mutation is capable of driving all the different MPN through ligand-independent activation of erythropoietin (EPO), thrombopoietin (TPO), and granulocyte-colony stimulating factor (G-CSF) tyrosine-kinase receptors. This evidence concerns the gene CSF3 and myeloproliferative neoplasm.